![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » EVOTEC ANNOUNCES RESULTS OF ALZHEIMER'S TREATMENT STUDY
EVOTEC ANNOUNCES RESULTS OF ALZHEIMER'S TREATMENT STUDY
August 9, 2006
Evotec has announced the successful completion of a Phase I trial of EVT 101, an NR2B subtype-specific NMDA receptor antagonist, for the treatment of Alzheimer's disease and/or neuropathic pain. A total of 90 healthy young and elderly subjects received single and multiple ascending doses of the compound. In all subjects the drug was well-absorbed, achieved good exposure levels and was well-tolerated with no significant adverse events. In both the young and elderly subjects, the compound had a good pharmacokinetic profile, with an 11-hour half-life consistent with once or twice daily oral dosing.
EVT 101 is a highly potent and selective antagonist of NR2B subunit containing NMDA receptors. In preclinical models, the compound has potent beneficial effects, an improved side effect profile compared with non-selective NMDA receptor antagonists and good oral bioavailability.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct